Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daratumumab + rituximab
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Daratumumab + rituximab is a combination of two monoclonal antibodies used off-label for the treatment of certain immune-mediated and refractory diseases, such as multidrug-resistant nephrotic syndrome and posttransplant recurrent focal segmental glomerulosclerosis. Daratumumab targets CD38, a glycoprotein highly expressed on plasma cells, leading to their depletion through mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and induction of apoptosis. Rituximab targets CD20 on B lymphocytes, resulting in B-cell depletion primarily via ADCC and CDC. The rationale for combining these agents is to target both mature B cells (via anti-CD20) and long-lived plasma cells (via anti-CD38), aiming for more comprehensive immunosuppression in refractory conditions[1][3][4][8].
- Other names
- daratumumab + rituximab combination
02
Targets
CD38 (Cluster of Differentiation 38)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on daratumumab + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daratumumab + rituximab.